SeaStar Medical Holding Corporation (ICU) is a commercial-stage medical device company developing the Selective Cytopheretic Device (SCD), a cell-directed extracorporeal therapy aimed at reducing the consequences of hyperinflammation on vital organs. It is a stock, not an ETF.
Coverage is thin. Independent aggregator data from S&P Global points to two tracked 12-month price targets: $8 on the low end and $12 on the high end, for a calculated mean of $10. Maxim Group analyst Anthony Vendetti maintains a Buy rating and raised his target to $8 from $6 on May 14, 2026, citing better-than-expected first-quarter revenue, gross margin, and loss per share, while lifting the firm's 2026 and 2027 revenue estimates. A second, higher $12 objective rounds out the range. Because only two targets exist, the $10 mean should be read as a rough benchmark, not a robust, widely followed consensus.
Shares recently traded near $1.90, down sharply over the trailing year. Reaching $10 would require an increase of about 426%, which qualifies as a very large move. SeaStar's pediatric device has received Humanitarian Device Exemption (HDE) approval for acute kidney injury, and the company is working toward broader adult indications. Yet the path to $10 is fundamentally different from a routine re-rating: it would require a multiple-fold expansion in the stock price on a market capitalization of roughly $10 million, sustained revenue growth from a very small base, and meaningfully narrower losses.
ICU trades near its recent and 52-week lows, in the low single digits after a prolonged decline. Long-term chart structure is distorted by multiple reverse splits, which makes durable support and resistance levels unreliable for this name. The $8 and $12 price targets sit far above the current trading range and should be treated as valuation benchmarks rather than nearby technical milestones. Investors should watch whether the stock can hold above the roughly $1.84-to-$1.90 zone that has marked its recent floor.
Analyst price targets generally reflect a research horizon of roughly 12 months, and the two tracked targets here fall within that convention. Because coverage is so limited, the actual assumptions behind each target vary materially. Key items to monitor include quarterly revenue and loss-per-share trends, any guidance or analyst target revisions, regulatory and clinical updates for the SCD platform, financing and dilution announcements, and broader risk appetite for speculative healthcare stocks.
For traders seeking a more dynamic view, AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The system is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning. Because signals update as conditions evolve, they can complement fundamental research on names like ICU.
The $10 central target is the mean of two widely separated analyst objectives, $8 and $12, and implies a very large move of roughly 426% from a recent price near $1.90. Support rests on early SCD commercialization, revenue beats, and a recent target increase from Maxim Group, while the principal obstacles are recurring losses, a thin balance sheet, a reverse-split history, and extremely limited coverage. The wide target range reflects genuine disagreement and uncertainty rather than a firm directional signal. Whether ICU approaches $10 will depend on sustained revenue growth, narrower losses, and new regulatory or commercial milestones, none of which is assured. Investors should monitor upcoming earnings, analyst revisions, and any financing developments before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ICU has been closely correlated with CANF. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if ICU jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To ICU | 1D Price Change % | ||
|---|---|---|---|---|
| ICU | 100% | -3.06% | ||
| CANF - ICU | 93% Closely correlated | -1.19% | ||
| APVO - ICU | 85% Closely correlated | -4.42% | ||
| GNPX - ICU | 82% Closely correlated | +1.46% | ||
| TNXP - ICU | 77% Closely correlated | -8.69% | ||
| LONA - ICU | 62% Loosely correlated | -10.07% | ||
More | ||||